Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2023 21:54 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B, measured during oral glucose tolerance testing...
June 20, 2023 16:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023

New clinical data from COVALENT-111 will be unveiled during a late-breaking poster presentation at ADA’s Scientific SessionsBMF-219, an orally delivered novel covalent menin inhibitor, is designed to...
May 02, 2023 16:01 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights

Reported initial positive clinical data from first two cohorts of Phase II of ongoing Phase I/II study (COVALENT-111) of BMF-219, Biomea’s lead investigational, orally administered covalent menin...
May 01, 2023 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

BMF-500, a novel 3rd generation covalent inhibitor of fms-like tyrosine kinase 3 (FLT3), is the second investigational compound, discovered and developed by Biomea’s FUSION™ System, to advance to the...
April 19, 2023 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June

New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the Scientific SessionsBiomea to hold an investor and KOL event during the Scientific Sessions ...
April 13, 2023 16:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting

Abstract 473 highlights the dose dependent reduction of menin target genes in ex vivo chronic lymphocytic leukemia (CLL) patient samples treated with BMF-219, an investigational covalent inhibitor....
April 13, 2023 09:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and...
March 29, 2023 23:15 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock

REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...
March 29, 2023 06:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...
March 28, 2023 16:02 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2 diabetes...